Jiang et al. showed that the MAPK pathway had the potential to stimulate PD-L1 expression in melanoma cells that had developed resistance to BRAF inhibition, suggesting that targeting the MAPK pathway could enhance the tumor response to immunotherapy [76]. This evidence concerns the gene CD274 and neoplasm.